Study Design
This was a 52-week randomised, double-blind, parallel-group,
active-controlled, non-inferiority trial with a 156-week extension
period that evaluated dapagliflozin versus glipizide as
add-on therapies to metformin in adult patients whose type 2
diabetes was inadequately controlled by metformin alone.